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Abstract Antibodies that recognise the active phosphorylated
forms of mitogen-activated protein kinase (MAPK) kinase 5
(MKK5) and extracellular signal-regulated kinase 5 (ERK5) in
untransfected cells have been exploited to show that the
epidermal growth factor (EGF)-induced activation of MKK5
and ERK5 occurs subsequent to the activation of ERK1 and
ERK2 in HeLa cells. The drugs U0126 and PD184352, which
prevent the activation of MKK1 (and hence the activation of
ERK1/ERK2), also prevent the activation of MKK5, although
higher concentrations are required. Our studies define physio-
logical targets of the MKK5/ERK5 pathway as proteins whose
phosphorylation is largely prevented by 10 WM PD184352, but
unaffected by 2 WM PD184352. Surprisingly, 2 WM PD184352
prolongs the activation of MKK5 and ERK5 induced by EGF or
H2O2, indicating negative control of the MKK5/ERK5 pathway
by the classical MAPK cascade. Our results also indicate that
ERK5 is not a significant activator of MAPK-activated protein
kinase-1/RSK in HeLa cells. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
Key words: Mitogen-activated protein kinase;
Mitogen-activated protein kinase kinase 5;
Extracellular signal-regulated kinase 5; BMK1; PD184352
1. Introduction
The classical Ras-dependent mitogen-activated protein ki-
nase (MAPK) cascade plays a key role in triggering the pro-
liferation of some cells and the di¡erentiation of others. The
conversion of Ras to its active GTP-bound state leads to the
sequential activation of the protein kinases Raf, MAPK ki-
nase 1 (MKK1, also called MEK), and extracellular signal-
regulated kinases 1 and 2 (ERK1, ERK2). ERK1/ERK2 then
modulate the functions of proteins that are critical for prolif-
eration and di¡erentiation.
The uncontrolled activation of the classical MAPK cascade,
caused, for example, by the overexpression or mutation of
growth factor receptors and/or the mutation of Ras to con-
stitutively active forms, is a cause of cell transformation and
cancer. Two compounds, PD98059 and U0126, suppress acti-
vation of the MAPK cascade by binding to MKK1, thereby
preventing its activation by Raf [1,2], and reverse the pheno-
type of Ras-transformed cell lines [3]. Moreover, PD184352, a
more potent compound that acts in the same way [2], inhibits
the growth of human colon cancers implanted into mice, with-
out obvious toxic side e¡ects [4]. These observations suggest
that inhibitors of the classical MAPK cascade might be useful
for the treatment of some types of cancer.
Recently, a potential problem in using PD98059 and U0126
to identify physiological roles of the MAPK cascade has aris-
en, with the report that they also inhibit the activation of
ERK5, another MAPK family member [5]. ERK5 is activated
by MKK5 [6] in response to epidermal growth factor (EGF)
[7] via a separate Ras-dependent pathway [5]. ERK5 can also
be activated in response to osmotic and oxidative stress [8].
MKK5 is not activated by Raf [9] but by co-transfection with
MEKK3 [10] or MEKK2 [11]. However, whether these and/or
other protein kinases activate MKK5 in vivo has yet to be
established. These ¢ndings raise the question of whether the
e¡ects of PD98059 and U0126 on cells, which have been re-
ported in over 2000 papers, are caused by inhibition of the
classical MAPK cascade or by inhibition of the MKK5/ERK5
cascade.
In this paper, we have studied the e¡ects of PD98059,
U0126 and PD184352 on the MKK5/ERK5 cascade in
HeLa cells, by using phospho-speci¢c antibodies capable of
detecting the endogenous MKK5 and ERK5 proteins. We
demonstrate that all three compounds are weaker inhibitors
of the MKK5/ERK5 pathway than the classical MAPK cas-
cade. Interestingly, PD184352 blocks activation of the classi-
cal MAPK cascade at concentrations where the activation of
MKK5 and ERK5 is una¡ected. This ¢nding should aid the
identi¢cation of the physiological substrates of ERK5 and has
led us to discover that the classical MAPK cascade exerts a
negative in£uence on the activation of MKK5 and ERK5 in
HeLa cells.
2. Materials and methods
2.1. Materials
EGF, microcystin-LR, and reagents for cell culture were purchased
from Life Technologies (Paisley, UK), PD98059 and U0126 from
Calbiochem (Nottingham, UK) and hydrogen peroxide and 12-O-tet-
radecanoyl phorbol 13-acetate (from Sigma (Poole, UK). ‘Complete’
protease inhibitor cocktail tablets were from Roche (Lewes, Sussex,
UK). Precast 4^12% Bis-Tris gradient SDS polyacrylamide gels were
from Invitrogen. All the peptides used in this study were synthesised
by Dr G. Bloomberg (University of Bristol, UK).
2.2. Cell culture, stimulation and cell lysis
HeLa cells were obtained from the European Tissue Culture Col-
lection and maintained in 5% CO2 in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% (v/v) foetal calf serum and 2 mM
L-glutamine.
Prior to stimulation, the cells were cultured overnight in the absence
of serum. PD184352 and U0126 were dissolved in dimethyl sulphoxide
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(DMSO) at a concentration of 10 mM, and PD98059 at 50 mM.
Where indicated, aliquots of these inhibitors in DMSO, or the equiv-
alent volume of DMSO as a control, were added to the culture me-
dium 60 min prior to stimulation. The cells were then stimulated (in
the continued presence or absence of inhibitors) with the indicated
agonists and lysed in ice-cold 50 mM Tris^HCl pH 7.5, 1 mM EGTA,
1 mM EDTA, 1% (w/v) Triton X-100, 10 mM sodium glycerophos-
phate, 1 mM sodium orthovanadate, 50 mM sodium £uoride, 5 mM
sodium pyrophosphate, 0.27 M sucrose, 1 WM microcystin-LR, ‘Com-
plete’ protease inhibitor cocktail (one tablet per 50 ml) and 0.1% (v/v)
2-mercaptoethanol. The lysates were centrifuged at 4‡C for 5 min at
13 000Ug and the supernatants frozen in liquid nitrogen and stored at
380‡C. Protein concentrations were determined according to the
Bradford method.
2.3. Expression and puri¢cation of recombinant His-ERK5
The cDNA encoding full-length ERK5 [6] was ampli¢ed by PCR
from a pCMV5-HA-ERK5 vector and cloned into pFASTBAC1. This
vector was then used to express and purify recombinant ERK5 pre-
ceded by six histidine residues (His-ERK5) in Sf21 cells using the Bac-
to-Bac system (Life Technologies, Paisley, UK), as described previ-
ously [14].
2.4. Antibodies
A phosphopeptide corresponding to residues 214^225 of human
ERK5, phosphorylated on Thr219 and Tyr221 (HQYFMT*EY*
VATR, where the phosphorylated residues are marked with asterisks)
was used to generate a phospho-speci¢c ERK5 antibody, using the
procedure described previously for phospho-speci¢c c-Jun N-terminal
kinase antibodies [14]. The phospho-speci¢c ERK5 antibody also rec-
ognises phosphorylated ERK1 and ERK2. A phosphopeptide corre-
sponding to residues 306^320 of human MKK5, phosphorylated on
Ser311 and Thr315 (TQLVNS*IAKT*YVGTN) was used to generate
a phospho-speci¢c MKK5 antibody in the same way. Polyclonal anti-
ERK5 antibodies were also raised in sheep against the His-ERK5
protein and a⁄nity-puri¢ed by chromatography on His-ERK5-aga-
rose. All antibodies were used at a concentration of 0.5^2 Wg/ml.
A⁄nity-puri¢ed anti-sheep antibodies coupled to horseradish peroxi-
dase were purchased from Pierce (Rockford, IL, USA) and used at
dilutions of 1:5000 (phospho-speci¢c antibodies) or 1:15 000 (anti-
ERK5 antibody). Immunoreactive proteins were detected by enhanced
chemiluminescence (Amersham Pharmacia Biotech, Little Chalfont,
UK).
3. Results
3.1. Generation of phospho-speci¢c antibodies that recognise
the activated forms of MKK5 and ERK5
In order to study the e¡ects of PD98059, U0126 and
PD184352 on the MKK5/ERK5 pathway, we ¢rst raised anti-
bodies capable of recognising the phosphorylated forms of
these enzymes (see Section 2). Although the activating phos-
phorylation sites on MKK5 have not yet been identi¢ed di-
rectly, by analogy with other MKK family members, they
were assumed to be the serine and threonine residues that
lie in positions equivalent to Ser217 and Ser221 of MKK1,
the residues that are phosphorylated by Raf [12]. Similarly,
the sites on ERK5 that are phosphorylated by MKK5 have
not been identi¢ed directly, but are assumed to be the threo-
nine and tyrosine residues of the Thr-Glu-Tyr motif that are
present at equivalent positions to the Thr-Glu-Tyr sequence in
ERK1 and ERK2 that is phosphorylated by MKK1 [6,13].
Using these antibodies, we were able to detect proteins in
HeLa cell extracts that became phosphorylated in response to
Fig. 1. Activation of the MKK5/ERK5 pathway by EGF and hy-
perosmotic stress. HeLa cells were serum-starved overnight, then
stimulated with 100 ng/ml EGF (A) or 0.5 M sorbitol (B) for the
times indicated. Phosphorylation of the endogenous MKK5 and
ERK5 was then examined by immunoblotting with an antibody that
recognises phosphorylated ERK5 (P-ERK5) and dephosphorylated
ERK5 equally well (upper panel in A and B) and with phospho-spe-
ci¢c antibodies that recognise the active, phosphorylated forms of
ERK5, MKK5 and ERK1/ERK2. Similar results were obtained in
several independent experiments.
Fig. 2. Inhibitors of the classical MAPK pathway are less e¡ective
at suppressing the activation of the MKK5/ERK5 pathway in HeLa
cells. The cells were serum-starved overnight, pretreated for 1 h
with the indicated concentrations of PD98059 (A), U0126 (B) or
PD184352 (C), then stimulated for 10 min with 100 ng/ml EGF.
Following cell lysis, the phosphorylation states of the endogenous
MKK5 and ERK5 were examined by immunoblotting with an anti-
body that recognises phosphorylated ERK5 (P-ERK5) and dephos-
phorylated ERK5 equally well (upper panels) and with phospho-
speci¢c antibodies that recognise the phosphorylated forms of
ERK5, MKK5 and ERK1/ERK2. Similar results were obtained in
several independent experiments.
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signals (EGF and osmotic stress) that are known to activate
the MKK5/ERK5 pathway and which migrated on SDS poly-
acrylamide gels with the molecular masses expected for
MKK5 and ERK5 (Fig. 1). The phosphorylation of ERK5
could also be detected by a small decrease in its electropho-
retic mobility using another antibody that recognises the
phosphorylated and dephosphorylated forms of the protein
equally well. After stimulation with EGF, or exposure to os-
motic stress, ERK5 was transformed into a species of slightly
lower electrophoretic mobility which comigrated with the
band detected with the phospho-speci¢c antibody. Similarly,
an antibody that recognises the phosphorylated and dephos-
phorylated forms of MKK5 equally well also recognised a
band in HeLa extracts that comigrated with that detected
with the MKK5 phospho-speci¢c antibody (data not shown).
The activation of MKK5 occurred slightly earlier than the
activation of ERK5, as expected, if MKK5 lies upstream of
ERK5 in the pathway. These experiments indicate that the
phospho-proteins detected by the antibodies are indeed
MKK5 and ERK5.
The amino acid sequences surrounding the phosphorylation
sites on ERK1, ERK2 and ERK5 are similar. For this reason,
the phospho-speci¢c antibody that recognised ERK5 also rec-
ognised ERK1 and ERK2, allowing the activation of ERK1/
ERK2 and ERK5 to be visualised simultaneously on the same
immunoblot. The EGF-induced activation of ERK5 in HeLa
cells was almost maximal 2 min after stimulation with EGF,
but the activation of ERK5 was only maximal after 15 min
(Fig. 1A). When the cells were exposed to 0.5 M sorbitol, an
osmotic stress (Fig. 1B), the activations of ERK1/ERK2 and
ERK5 were both maximal after 15^20 min.
3.2. E¡ects of PD98059, U0126 and PD184352 on the
activation of MKK5 and ERK5
Pre-incubation of HeLa cells with PD98059 or U0126 in-
hibited the EGF-induced phosphorylation of ERK5, as ex-
pected from an earlier study in COS7 cells [5]. However, in
our experiments, both inhibitors were less e¡ective at sup-
pressing the phosphorylation of MKK5 and ERK5 than the
activation of ERK1 and ERK2, and inhibition of MKK5 and
ERK5 phosphorylation by PD98059 was weak (Fig. 2A,B).
PD184352 also inhibited the phosphorylation of ERK5.
However, whereas 1^2 WM PD184352 was su⁄cient to block
the classical MAPK cascade, as judged by suppression of the
phosphorylation of ERK1/ERK2 (Fig. 2) and activation of
one of their substrates, MAPK-activated protein kinase 1
(MAPKAP-K1, also called RSK) (Fig. 3A). It was necessary
to increase PD184352 to 10 WM to largely suppress the acti-
vation of MKK5 and ERK5 (Fig. 2). U0126 and PD184352
also blocked the activation of MKK5, at concentrations sim-
ilar to those needed suppress the activation of ERK5 (Fig. 2).
3.3. Activation of the MKK5/ERK5 pathway is inhibited by the
classical MAPK cascade
Although the activation of ERK5 and MKK5 induced by
EGF was transient, we found that activation was more pro-
Fig. 3. Inhibition of the classical MAPK pathway causes a more
sustained activation of the MKK5/ERK5 pathway after stimulation
with EGF. A: HeLa cells were serum-starved overnight, pretreated
for 1 h without (closed circles) or with 2 WM PD184352 (open
circles), then stimulated with 100 ng/ml EGF for the times indi-
cated. MAPKAP-K1b (RSK2) was immunoprecipitated from the
cell lysates (50 Wg protein) using an antibody raised against the pep-
tide RNQSPVLEPVGRSTLAQRRGIKK [1] and then assayed with
the peptide Crosstide (GRPRTSSFAEG) as described [16,17]. One
unit of activity (U) was that amount which catalysed the phosphor-
ylation of 1 nmol of Crosstide in 1 min in the standard assay. The
protein concentration in the extract was determined by the method
of Bradford. B: Same as A, except that aliquots of the extracts
were denatured in SDS, electrophoresed on SDS polyacrylamide
gels and transferred to nitrocellulose. Phosphorylation of the endog-
enous ERK5 and MKK5 was then monitored by immunoblotting
with an antibody that recognises phosphorylated ERK5 (P-ERK5)
and dephosphorylated ERK5 equally well (upper two panels) and
with a phospho-speci¢c antibody that recognises the phosphorylated
form of MKK5 (lower two panels). Similar results were obtained in
several independent experiments.
Fig. 4. Inhibition of the classical MAPK pathway allows a more
sustained activation of the MKK5/ERK5 pathway by hydrogen per-
oxide. HeLa cells were serum-starved overnight, pretreated for 1 h
without or with 2 WM PD184352, then stimulated with or without
1 mM hydrogen peroxide for the times indicated. Phosphorylation
of the endogenous MKK5 and ERK5 was then examined by immu-
noblotting with an antibody that recognises phosphorylated
(P-ERK5) and dephosphorylated ERK5 equally well (upper panel),
an antibody that recognises the phosphorylated form of MKK5
(middle panel) and an antibody that recognises the phosphorylated
form of ERK1/ERK2 (lower panel). Similar results were obtained
in several independent experiments.
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longed if the cells were incubated with 2 WM PD184352 (Fig.
3B). Thus the classical MAPK cascade has a negative e¡ect on
the EGF-induced activation of the MKK5/ERK5 pathway.
However, the e¡ect is not EGF-speci¢c, because the activation
of MKK5 and ERK5 induced by H2O2, an oxidative stress,
was also more prolonged in the presence of 2 WM PD184352
(Fig. 4).
4. Discussion
Nishida and co-workers [5] reported that the drugs
PD98059 and U0126 inhibited the EGF-induced activation
of transfected ERK5 in COS7 cells at concentrations similar
to those which suppressed activation of the classical MAPK
cascade. In this paper, we con¢rmed that PD98059 and U0126
inhibited activation of the endogenous ERK5 in HeLa cells,
but only at higher concentrations than those required to pre-
vent the activation of ERK1/ERK2. This was also true for
PD184352, a more potent inhibitor of the classical MAPK
cascade [4]. We have reported previously that PD98059,
U0126 and PD184352 suppress activation of the classical
MAPK cascade in cell-based assays by binding to MKK1,
thereby preventing the phosphorylation and activation of
MKK1 by Raf and other upstream activators [1,2]. In the
present study, we showed that the same three drugs prevent
the activation of ERK5 by suppressing activation of the en-
dogenous MKK5 in HeLa cells (Fig. 2). Since the catalytic
domains of MKK5 and MKK1 show 46% amino acid se-
quence identity, it seems likely that these compounds also
exert their e¡ects by binding to MKK5, thereby preventing
its phosphorylation and activation.
The activation of ERK1 and ERK2 was completely sup-
pressed by incubating HeLa cells with 1^2 WM PD184352, at
which concentration the activation of MKK5 or ERK5 was
not reduced (Figs. 2 and 3). The activation of MKK5 and
ERK5 was only suppressed at 10 WM PD184352. These ob-
servations may facilitate identi¢cation of physiological sub-
strates of ERK5. Moreover, we found that blocking the acti-
vation of ERK1 and ERK2 by incubating HeLa cells with 2
WM PD184352 prolonged the activation of MKK5 and ERK5
by either EGF (Fig. 3B) or hydrogen peroxide (Fig. 4). These
observations demonstrate that one or more components of the
classical MAPK cascade have a negative e¡ect on activation
of the MKK5/ERK5 pathway. To our knowledge, this is the
¢rst evidence of ‘crosstalk’ between these two MAPK cas-
cades.
The growth factor-induced activation of MAPKAP-K1
(also called RSK) is thought to be mediated in vivo by
ERK1/ERK2, because its activation is prevented by
PD98059 [1]. It has been reported that MAPKAP-K1/RSK
can also be activated by co-transfection with ERK5 and a
constitutively active mutant of MKK5, suggesting that MAP-
KAP-K1/RSK might be activated by the MKK5/ERK5 path-
way as well as, or instead of, the MKK1-ERK1/ERK2 path-
way [15]. However, we found that the EGF-induced activation
of MAPKAP-K1 was blocked by prior incubation of the cells
with 2 WM PD184352 (Fig. 3A), even though the activation of
ERK5 was just as high and more prolonged under these con-
ditions. Thus ERK5 makes a negligible contribution to the
EGF-induced activation of MAPKAP-K1 in HeLa cells.
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